UNSPSC 51162411: Dextromethorphan/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.

UNSPSC 51162411 Dextromethorphan/phenylpropanolamine is a Commodity code that in practice covers pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter health products procured by state and local health agencies, county health departments, and cooperative purchasing alliances. State and local governments buying under this code seek pharmaceutical inventory for community health initiatives, emergency response programs, and broad distribution across participating government facilities. Issuing bodies include county health departments, state agencies administering cooperative purchasing vehicles, and multistate procurement alliances that aggregate demand across member jurisdictions.

Recent activity centers on Florida and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026 (though the solicitation summary contains an inconsistent 2023 date). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with a response deadline of March 26, 2026. Both procurements require vendors to demonstrate cGMP compliance, maintain authorized wholesaler relationships, and submit detailed product and pricing documentation. The MMCAP contract uses price competitiveness (75 percent weight) as the dominant evaluation criterion and reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.